Pluvicto in real-world prostate cancer survival
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well a drug called Pluvicto (Lu-PSMA-617) works in real life for men with advanced prostate cancer that has stopped responding to hormone therapy. It helps doctors understand how long people live after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of prostate cancer (metastatic castration-resistant prostate cancer or mCRPC).
- You have been treated with the drug Pluvicto (also called Lu-PSMA-617) for your prostate cancer.
- You are 18 years or older and are male.
- You have medical records or health plan coverage for at least 12 months before starting Pluvicto and at least 6 months after (unless you passed away).
- You do not have another active cancer (other than prostate cancer) in the last 3 years, and you are not currently in a different clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) who have already used certain treatments, including a newer drug called lutetium-177 PSMA-617. It aims to understand how these treatments work and what happens to patients over time.
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
This trial studies how well a radioactive drug called Pluvicto works in men with prostate cancer who also have kidney or bone marrow problems. You'll get the treatment and have several scans to see how the drug affects your body.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.